Staar Surgical CoSTAA +0.03%83 Return-on-Tangible-Equity is 6.63% as of Mar. 2026, which is 45% above its 10-year median of 4.58. GuruFocus rates STAA with a GF Score™ of 83/100 and a GF Value™ of $31.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Staar Surgical Co ranks worse than 64.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Staar Surgical Co's annualized net income for the quarter that ended in Mar. 2026 was $20.8 Mil. Staar Surgical Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $314.0 Mil. Therefore, Staar Surgical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 6.63%.
The historical rank and industry rank for Staar Surgical Co's Return-on-Tangible-Equity or its related term are showing as below:
STAA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -33.67 Med: 4.58 Max: 13.43
Current: -6.32
During the past 13 years, Staar Surgical Co's highest Return-on-Tangible-Equity was 13.43%. The lowest was -33.67%. And the median was 4.58%.
STAA's Return-on-Tangible-Equity is ranked worse than 64.25% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs STAA: -6.32
Staar Surgical Co (NAS:STAA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Staar Surgical Co Return-on-Tangible-Equity Related Terms
Staar Surgical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Staar Surgical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STAA vs BLFS, ATRC, KMTS: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.63% mean?
Staar Surgical Co (STAA) has a Return-on-Tangible-Equity of 6.63% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Staar Surgical Co and its competitors. This is 45% above median its historical median of 4.58. According to the industry distribution chart, Staar Surgical Co ranks #487 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is Staar Surgical Co's Return-on-Tangible-Equity too high?
Staar Surgical Co's current Return-on-Tangible-Equity of 6.63% is 45% above median its 10-year median of 4.58. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Staar Surgical Co's value of 6.63% is 62.5% above this industry median. Based on the distribution chart, Staar Surgical Co ranks #487 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Staar Surgical Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's Return-on-Tangible-Equity compare to BLFS and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Staar Surgical Co ranks #487 out of 758 companies for Return-on-Tangible-Equity. This places Staar Surgical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Staar Surgical Co's value of 6.63% is 62.5% above this benchmark. While the company's 10-year median is 4.58 vs. the industry median of 4.08, Staar Surgical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Staar Surgical Co's current Return-on-Tangible-Equity of 6.63% is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Staar Surgical Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Staar Surgical Co's current Return-on-Tangible-Equity is 6.63%, which is 45% above median its own 10-year median of 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (STAA) is currently considered Fairly Valued. The stock's GF Value™ is $31.63, compared to a current price of $28.71 — trading 9.2% below its estimated fair value. The current Return-on-Tangible-Equity is 6.63%, which is 45% above median its 10-year median of 4.58 and 62.5% above the Medical Devices & Instruments industry median of 4.08. Staar Surgical Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Staar Surgical Co (STAA), the current Return-on-Tangible-Equity is 6.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (STAA) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of $28.71 is trading 9.2% below its estimated GF Value™ of $31.63.
GuruFocus considers Staar Surgical Co to be Fairly Valued.
Key valuation signals for STAA:
Return-on-Tangible-Equity: 6.63% (45% above median its 10-year median of 4.58)
GF Value™: $31.63 vs. price of $28.71 (9.2% below fair value)
Industry Position: 62.5% above the Medical Devices & Instruments median (#487 of 758)
No single metric tells the full story. See the STAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
83GF Score
Get the complete analysis for STAA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STAA has been successfully added to your 
